Since its founding in 1717 as an apothecary in Dosho-machi, Osaka, Ono has been dedicated to improving people's health through medicines for over 300 years.
Guided by our corporate philosophy of "Dedicated to the Fight against Disease and Pain," we are advancing as a Global Specialty Pharma that continues to deliver original and innovative medicines to patients around the world.
We have designated oncology, immunology & inflammation, and neurology as priority areas for research and development, and are actively working to create medicines that truly benefit patients in areas where medical needs are high and where patient satisfaction with current treatment is low. In addition, we are working to further improve our drug discovery capabilities by incorporating revolutionary drug discovery seeds and world-leading technologies through collaborations, as well as strategic partnerships, with academia and bioventures both in Japan and overseas.
In FY2024, we welcomed Deciphera Pharmaceuticals, Inc. in the United States to the Ono Group, securing our clinical development and sales capabilities in the United States and Europe. This has enabled us to establish a corporate structure capable of accelerating our global business operations.
By bringing in even more highly specialized talent, we will carry forward our commitment of being “passionate challengers” on a global scale.
Through our business of delivering new medicines to society, Ono strives to remain a company that contributes to solving societal issues. Through our ongoing efforts in environmental, social, and governance initiatives, we seek to be a company that is trusted by and essential to society. That is the kind of company we aspire to be.
Moving forward, we will continue to keep patients in our mind, strive to address unmet medical and societal needs, and bring health, happiness, and hope to people through the power of new medicines.
Gyo Sagara
Representative Director, Chairman of the Board & CEO
With the mission of continuing to be a pharmaceutical company that relentlessly pursues innovative medicines, Ono Pharmaceutical is advancing toward becoming a global specialty pharma that independently discovers new drugs and delivers new treatments to patients around the world. The challenge of venturing into the unknown continues to this day, and it is my role as COO to convert that journey into tangible growth.
There are three main reasons why the addition of Deciphera to our Group in 2024 was significant. First, it further expands our pipeline and product lineup, mainly in the field of oncology. Second, it provides us with a development and sales platform centered in Europe and the United States. Third, it enhances the Ono Group’s overall research and development capabilities by integrating Deciphera’s drug discovery capabilities. We will fully leverage these strengths to establish a solid presence in rapidly expanding Western markets.
To get our global expansion on track, it is essential to have multiple product lines and a structure that can meet the diverse needs of patients and healthcare sites in the target regions. Ono Pharmaceutical’s first-in-class drug discovery capability, which grasps the essence of diseases and creates entirely new mechanisms of action, and Deciphera’s ability to develop drugs using its unique technology. By respecting and combining the respective strengths of our companies, we will continue to deliver innovative medicines to patients around the world.
In addition, in an environment where diverse human resources work together, a culture of recognizing differences and respecting one another is fundamental. What we aim for is not simply a top-down model, but an organizational culture that values bottom-up input and enthusiasm from the field. Ono Pharmaceutical seeks to foster an environment that balances our own identity with respect for others, so that the integration of the two companies leads to success.
Ono Pharmaceutical’s strengths lie in our patient-centered values, our spirit of innovation and challenge, and our corporate culture where diverse human resources support, complement and elevate each other as a team. Going forward, we aspire to leverage these strengths to remain a company where the growth of each employee and the organization synergistically drive ongoing contributions to society.
Toichi Takino, Ph.D.
Representative Director, President & COO